Multicellular living organisms and unmodified parts thereof and – Nonhuman animal – Transgenic nonhuman animal
Reexamination Certificate
1998-04-01
2001-04-17
Chambers, Jasemine (Department: 1632)
Multicellular living organisms and unmodified parts thereof and
Nonhuman animal
Transgenic nonhuman animal
C800S003000, C800S009000, C800S021000, C800S022000, C800S025000, C435S455000, C435S320100, C424S009200
Reexamination Certificate
active
06218597
ABSTRACT:
FIELD OF THE INVENTION
The present invention relates to a transgenic model of heart muscle disease (cardiomyopathy) and heart failure. The present invention also relates to gene therapy for the treatment of heart failure.
BACKGROUND OF THE INVENTION
Heart failure is a pathophysiological condition in which the heart fails to pump blood at a rate commensurate with the requirements of the metabolizing tissues of the body. Heart failure is a principal complication of virtually all forms of heart disease.
In the failing human heart, numerous changes occur in receptor signal transduction pathways. In particular, there is impairment of the myocardial &bgr;-adrenergic receptor (&bgr;AR) system.
Receptors coupled to heterotrimeric guanine nucleotide-binding proteins (G proteins), such as the adrenergic receptors, increase cellular concentrations of second messengers, such as cyclic adenosine 3′, 5′-monophosphate (cAMP), thereby regulating cellular function. The binding of the catecholamines norepinephrine and epinephrine to &bgr;ARs in the heart stimulates adenylyl cyclase, raises the concentration of cAMP, and increases cardiac contractility. Increased secretion of catecholamines and stimulation of myocardial &bgr;ARs are critical for augmenting cardiac function during exercise and stress.
One of the best documented changes that occurs in heart failure is the differential down-regulation of the &bgr;
1
-adrenergic receptor (&bgr;
1
AR). This is accompanied by an uncoupling of the &bgr;
2
-adrenergic receptor (&bgr;
2
AR) and, perhaps, also the &bgr;
1
AR, from adenylyl cyclase stimulation so that the failing heart is less able to respond to &bgr;AR agonists and to the demands of stress and exercise. In addition, the &bgr;
1
AR signal transduction pathway is presumed to be responsible for producing adverse biological effects in cardiac myocytes associated with chronic activation of the adrenergic nervous system. Therefore, chronic overstimulation of this receptor pathway may contribute significantly to the downward progression of heart failure.
Bertin et al. have described a transgenic mouse overexpressing human &bgr;
1
AR. Bertin et al.,
Cardiovasc. Res
., 27, 1606-1612 (1993); PCT application WO 94/04668. Receptor overexpression was targeted exclusively to the atria by using the human a trial natriuretic factor promoter. Statistically significant phenotypic effects were not generated, although an excess of premature supraventricular beats was observed in 43% of the transgenic mice.
Milano et al. have described the creation of a transgenic mouse overexpressing the human &bgr;
2
AR using a murine &agr;-myosin heavy chain (&agr;MHC) promoter. Milano et al.,
Science
, 264, 582-586 (1994); Milano et al.,
J. Thoracic Cardiovasc. Surg
., 109, 236-241 (1995). The use of this promoter targeted gene expression to the myocardium, both in the atria and ventricles. Myocardial and ventricular function were reported to be enhanced. No pathologic changes were observed in mice up to four months of age. In particular, no heart failure or cardiomyopathic phenotype was reported.
Milano et al. suggest the potential of their approach for the treatment of heart failure by gene therapy. However, they teach against using genes coding for &bgr;
1
ARs (see page 583, second column of Milano et al.,
Science
, 264, 582-586 (1994)).
SUMMARY OF THE INVENTION
The invention provides a transgenic mouse having incorporated into its genome a transgene comprising a heart tissue-specific promoter operatively linked to a coding sequence comprising DNA coding for a &bgr;
1
-adrenergic receptor, the transgene being expressed in at least the myocardium of the heart of the transgenic mouse. The transgenic mouse of the invention can be used a model of heart muscle disease (cardiomyopathy) and may be used to study molecular and cellular aspects associated with heart muscle disease, to identify compounds useful for treating or preventing heart muscle disease, and to evaluate the effects of external factors (such as diet and exercise) on heart muscle disease. As the transgenic mouse of the invention ages, it developes into a model of heart failure and may be used to study molecular and cellular aspects associated with heart failure, to identify compounds useful for treating or preventing heart failure, and to evaluate the effects of external factors (such as diet and exercise) on heart failure. The transgenic mouse of the invention may also be used to study the effects associated with overexpression of &bgr;
1
-adrenergic receptors and to evaluate the effects of compounds which interact with &bgr;
1
-adrenergic receptors.
The invention further provides a transgenic mammal having incorporated into its genome a transgene comprising a heart tissue-specific promoter operatively linked to a coding sequence comprising DNA coding for a &bgr;
1
-adrenergic receptor, the transgene being expressed in at least the myocardium of the heart of the transgenic mammal. This transgenic mammal is also a model of heart muscle disease and heart failure.
Finally, the invention provides a method of treating heart failure in a mammal. The method comprises administering a transgene to the mammal, the transgene comprising a heart tissue-specific promoter operatively linked to a coding sequence comprising DNA coding for a &bgr;
1
-adrenergic receptor, the transgene being expressed in at least the myocardium of the heart of the mammal.
REFERENCES:
patent: 5252479 (1993-10-01), Srivastava
patent: 5399346 (1995-03-01), Anderson et al.
patent: 5460831 (1995-10-01), Kossovsky et al.
patent: 5521291 (1996-05-01), Curiel et al.
patent: 5559099 (1996-09-01), Wickham et al.
patent: 94/04668 (1994-03-01), None
patent: 96/14876 (1996-05-01), None
Bertin et al., 1993,Cardiovascular Research, 27:1606-1612.
Bisognane et al., Abstract for Biomedicine '97, Apr. 25-27, 1997.
Drazner et al., 1997,J. Clin. Invest., 99(2):288-296.
Gaudin et al., 1995,J. Clin. Invest., 95:1676-1683.
Iwase et al., 1996,Circulation Research, 78(4):517-524.
Kirshenbaum et al., 1993,J. Clin. Invest., 92:381-387.
Koch et al., 1995,Science, 268:1350-1353.
Milano et al., 1994,Science, 264:582-586.
Milano et al., 1994,Proc. Natl. Acad. Sci. USA, 91:10109-10113.
Milano et al., 1995,J. Thorac Cardiovasc Surg, 109:236-241.
Port et al.,JACC, 177A (abstract 831-6) (Feb. 1998).
Rohrer et al., 1996,Proc. Natl. Acad. Sci. USA, 93:7375-7380.
Samama et al., 1997,Proc. Natl. Acad. Sci. USA, 94:137-141.
Soloveva et al.,Mol Endo, 11(1):27-38.
Adolph et al,J. Biol. Chem., 268(8):5349-5352 (1993).
Frielle et al.,Proc. Natl. Acad. Sci. USA, 84:7920-7924 (1987).
Gulick et al.,J. Biol. Chem., 266(4):9180-9185 (1991).
Jaber et al.,Proc. Natl. Acad. Sci. USA, 93:12974-12979 (1996).
Kenakin,Pharmacological Reviews, 48(3):413-463 (1996).
Korzick et al.,Am. J. Physiol., 272(Heart Circ. Physiol.41):H590-H596 (1997).
Tate et al.,Eur. J. Biochem., 196:357-361 (1991).
Turki et al.,Proc. Natl. Acad. Sci. USA, 93:10483-10488 (1996).
Yoshikawa et al.,Eur. Heart Journal, 17(Supp B):8-16 (1996).
Hammer et al., Journal of Animal Science, vol. 63, pp. 269-278, 1986.*
Elbert et al., Molecular Endocrinology, vol. 2, pp. 277-283, 1988.*
Mullins et al., Journal of Clinical Investigations, 98, No. 11, pp. S37-S40, 1996.*
Wall, Theriogenology, vol. 45, pp. 57-68, 1996.*
Kapple et al., Current Opinion in Biotechnology, vol. 3, pp. 548-553, 1992.*
Strojek & Wagner, Genetic Engineering: Principles and Methods, vol. 10, pp. 221-246, 1988.
Bristow Michael R.
Port J. David
Chambers Jasemine
Fulbright & Jaworski LLP
Martin Jill D.
University Technology Corporation
LandOfFree
Transgenic model and treatment for heart disease does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Transgenic model and treatment for heart disease, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Transgenic model and treatment for heart disease will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2481246